Orforglipron + Placebo
Phase 3Recruiting 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerosis Cardiovascular Disease
Conditions
Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Trial Timeline
Dec 1, 2025 โ Aug 1, 2031
NCT ID
NCT07241390About Orforglipron + Placebo
Orforglipron + Placebo is a phase 3 stage product being developed by Eli Lilly for Atherosclerosis Cardiovascular Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07241390. Target conditions include Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07241390 | Phase 3 | Recruiting |
| NCT07223593 | Phase 3 | Recruiting |
| NCT07202884 | Phase 3 | Recruiting |
| NCT07153471 | Phase 3 | Recruiting |
| NCT06972472 | Phase 3 | Recruiting |
| NCT06972459 | Phase 3 | Recruiting |
| NCT06993792 | Phase 3 | Recruiting |
| NCT06952530 | Phase 3 | Recruiting |
| NCT06948435 | Phase 3 | Recruiting |
| NCT06948422 | Phase 3 | Recruiting |
| NCT06824051 | Phase 1 | Completed |
| NCT06672939 | Phase 3 | Recruiting |
| NCT06672549 | Phase 3 | Recruiting |
| NCT06649045 | Phase 3 | Active |
| NCT06584916 | Phase 3 | Completed |
| NCT06109311 | Phase 3 | Completed |
| NCT05971940 | Phase 3 | Completed |
| NCT05931380 | Phase 3 | Completed |
| NCT05869903 | Phase 3 | Active |
| NCT05872620 | Phase 3 | Completed |
Competing Products
20 competing products in Atherosclerosis Cardiovascular Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olmesartan medoxomil + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Pactimibe sulfate | Daiichi Sankyo | Phase 2/3 | 65 |
| Pactimibe | Daiichi Sankyo | Phase 2 | 52 |
| Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin | Daiichi Sankyo | Phase 3 | 77 |
| Micronized 17B-estradiol | Johnson & Johnson | Phase 2/3 | 65 |
| Rosuvastatin + placebo + aspirin + placebo | AstraZeneca | Approved | 85 |
| Rosuvastatin + Placebo | AstraZeneca | Approved | 85 |
| rosuvastatin + placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Vorapaxar + Placebo + Aspirin + Clopidogrel | Merck | Phase 2 | 52 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| lovastatin | Merck | Phase 2/3 | 65 |
| Ezetimibe + Placebo | Merck | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Niaspan | Merck | Pre-clinical | 23 |
| MK0633 | Merck | Phase 2 | 52 |